1.Human epidermal growth factor receptor 2 expression and associated factors in endometrial carcinoma
Shiyun ZHANG ; Shiyang JIANG ; Tingyan SHI
Chinese Journal of Clinical Medicine 2025;32(3):432-440
Objective To explore the expression of human epidermal growth factor receptor 2 (HER2) and its associations with clinical, pathological, and imaging characteristics in endometrial carcinoma (EC) patients. Methods A retrospective analysis was conducted on 214 patients with newly diagnosed EC treated at Zhongshan Hospital, Fudan University, from January 2022 to December 2024. HER2 expression was assessed using immunohistochemistry (IHC) staining, and its associations with clinical characteristics, histopathological and imaging features were analyzed. Results The HER2 expression rate (IHC score of 1+/2+/3+) in EC was 37.4% (80/214). HER2 expression was significantly associated with older age, advanced International Federation of Gynecology and Obstetrics (FIGO) stage, aggressive histological types, P53abn and low apparent diffusion coefficient (ADC) of preoperative pelvic magnetic resonance imaging (MRI). Multivariate analysis indicated that aggressive histological types (P=0.002) and low ADC of preoperative pelvic MRI (P=0.047) were independent factors associated with HER2 expression. Conclusions ADC of EC lesions may serve as a non-invasive predictive marker for HER2 expression, while histological type provides a critical basis for precisely guiding HER2 testing.
2.Research progress on the molecular mechanisms of cancer-associated fibroblasts mediating therapeutic resistance in gastric cancer and targeted strategies
Chinese Journal of Clinical and Experimental Pathology 2025;41(10):1357-1364
Cancer-associated fibroblasts(CAFs),as major components of the tumor microenvironment,play a pivotal role in therapeutic resistance in gastric cancer.Evidence shows that CAFs contribute to resistance through vari-ous multiple mechanisms,including exosomal signaling,metabolic reprogramming,extracellular matrix remodeling,and immune modulation.Although the regulatory network of CAFs is highly complex and the clinical translation of relat-ed therapeutic strategies remains challenging,precise targeting CAFs offers a promising avenue for overcoming drug re-sistance and improving patient outcomes.This review summarizes the molecular mechanisms by which CAFs mediate resistance and signaling pathways,biomarker-based immunotherapy,and emerging combination regimens,aiming to provide novel insights for gastric cancer treatment.
3.Association between the non-treatment threshold or upper limit of normal of alanine aminotransferase and liver pathological injury in patients with chronic hepatitis B virus infection and a persistently low level of alanine aminotransferase
Ming SHU ; Suwen JIANG ; Airong HU ; Qin CHEN ; Jialan WANG ; Menghan JIN ; Haojin ZHANG ; Shiqi YANG ; Shiyang FAN
Journal of Clinical Hepatology 2025;41(10):2044-2053
ObjectiveTo investigate the significance of different non-treatment thresholds or upper limits of normal (ULN) of alanine aminotransferase (ALT) in evaluating significant liver pathological injury in patients with chronic hepatitis B virus (HBV) infection, and to provide guidance for clinical diagnosis and treatment. MethodsThis study was conducted among 733 patients with chronic HBV infection who were hospitalized in Ningbo No. 2 Hospital from January 2015 to December 2023 and underwent liver biopsy and histopathological examination, and all patients had a persistent ALT level of ≤40 U/L and positive HBV DNA (>30 IU/mL). According to the treatment threshold or ULN of ALT, the patients were divided into group 1 with 575 patients (≤35 U/L for male patients, ≤25 U/L for female patients), group 2 with 430 patients (≤30 U/L for male patients, ≤19 U/L for female patients), group 3 with 443 patients (≤27 U/L for male patients, ≤24 U/L for female patients), group 4 with 446 patients (≤25 U/L), group 5 with 158 patients (>35 U/L for male patients, >25 U/L for female patients), and group 6 with 145 patients (>30 — ≤35 U/L for male patients, >19 — ≤25 U/L for female patients). Groups 2, 5, and 6 were compared to analyze the severity of liver pathological injury in patients with different ALT levels and the constituent ratio of patients with significant liver pathological injury, and groups 1, 2, 3, and 4 were compared to investigate the value of different ULN or non-treatment thresholds of ALT in determining liver inflammation grade (G), liver fibrosis stage (S), and the treatment indication based on liver pathology. The independent-samples t test was used for comparison of normally distributed continuous data between two groups; a one-way analysis of variance was used for comparison between multiple groups, and the least significant difference t-test or the Tambane’s test was used for further comparison between two groups; the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups, and the Kruskal-Wallis H test was used for comparison between multiple groups and further comparison between two groups; the chi-square test or the Fisher’s exact test was used for comparison of categorical data between groups; a Ridit analysis was used for comparison of ranked data. A multivariate Logistic regression analysis (forward stepwise) was performed with whether liver pathology met the treatment indication (≥G2 and/or ≥S2) as the dependent variable and related factors with a significant impact on the dependent variable (P <0.05) as the independent variable. The receiver operating characteristic (ROC) curve was plotted, and the area under the ROC curve (AUC), as well as sensitivity, specificity, positive predictive value, negative predictive value, positive likelihood ratio, and negative likelihood ratio, was used to assess the diagnostic value of different non-treatment thresholds of ALT. ResultsAmong the 733 patients, 259 (35.33%) had ≥G2 liver inflammation, 211 (28.79%) had ≥S2 liver fibrosis, and 306 (41.75%) had treatment indication (≥G2 and/or ≥S2). There was a significant difference in liver inflammation grade (G0 — G4) between groups 2, 5, and 6 (χ2=22.869, P <0.001), and there were also significant differences in the constituent ratios of patients with ≥G2 or ≥G3 liver inflammation between the three groups (χ2=21.742 and 14.921, P<0.001 and P=0.001). There was a significant difference in liver fibrosis stage (S0 — S4) between groups 2, 5, and 6 (χ2=16.565, P<0.001), and there were also significant differences in the constituent ratios of patients with ≥S2, ≥S3 or S4 liver fibrosis between the three groups (χ2=13.264, 13.050, and 6.260, P=0.001, 0.001, and 0.044). There were significant differences between groups 2, 5, and 6 in the constituent ratios of patients with or without treatment indication based on liver pathology (χ2=20.728, P<0.001). There were significant differences between groups 2, 5, and 6 in the constituent ratio of male patients (χ2=24.836, P<0.05), age (F=5.710, P<0.05), ALT (F=473.193, P<0.05), aspartate aminotransferase (AST) (F=107.774, P<0.05), ALT/AST ratio (F=40.167, P<0.05), γ-glutamyl transpeptidase (GGT) (H=15.463, P<0.05), aspartate aminotransferase-to-platelet ratio index (APRI) (H=63.024, P<0.05), and LIF-5 (5 indicators for liver inflammation and fibrosis) (H=46.397, P<0.05). In groups 1 — 4, compared with the patients without treatment indication, the patients with treatment indication had a significantly lower constituent ratio of patients with positive HBeAg, significantly lower levels of platelet count (PLT) and HBV DNA, and significantly higher age, ALT, AST, GGT, APRI, FIB-4, and LIF-5 (all P<0.05). The Logistic regression analysis showed that age (odds ratio [OR]=1.044, 95% confidence interval [CI]: 1.025 — 1.063, P<0.001), GGT (OR=1.022, 95%CI: 1.007 — 1.038, P=0.003), and HBV DNA (OR=0.839, 95%CI: 0.765 — 0.919, P<0.001) were influencing factors for treatment indication based on liver pathology in group 1; HBeAg (OR=1.978, 95%CI: 1.269 — 3.082, P=0.003), age (OR=1.048, 95%CI: 1.025 — 1.071, P<0.001), GGT (OR=1.016, 95%CI: 1.001 — 1.031, P=0.041), and PLT (OR=0.995, 95%CI: 0.991 — 1.000, P=0.049) were influencing factors in group 2; age (OR=1.040, 95%CI: 1.014 — 1.066, P=0.002), ALT (OR=1.047, 95%CI: 1.005 — 1.092, P=0.029), HBV DNA (OR=0.817, 95%CI: 0.736 — 0.907, P<0.001), and LIF-5 (OR=7.382, 95%CI: 1.151 — 47.330, P=0.035) were influencing factors in group 3; age (OR=1.054, 95%CI: 1.031 — 1.077, P<0.001), ALT (OR=1.061, 95%CI: 1.016 — 1.107, P=0.008), and HBV DNA (OR=0.825, 95%CI: 0.743 — 0.917, P<0.001) were influencing factors in group 4. The diagnostic performance for identifying ≥G2 liver inflammation, ≥S2 liver fibrosis, and treatment indication in groups 1 — 4 had an AUC of >0.7; group 1 showed the lowest sensitivity (28.76%) and the highest specificity, positive predictive value, positive likelihood ratio, and negative likelihood ratio in judging treatment indication; group 2 had the highest sensitivity and negative predictive value and the lowest negative likelihood ratio; groups 3 and 4 had similar diagnostic indicators. ConclusionIn patients with chronic HBV infection and a persistently low ALT level, the severity of liver histopathological injury and the constituent ratio of significant liver histopathological injury decrease with the reduction in ALT level. A higher non-treatment threshold or ULN of ALT can help to identify the patients requiring treatment (with a higher specificity), while a lower non-treatment threshold or ULN of ALT can help to identify the patients who do not require treatment (with a higher sensitivity).
4.Research progress on the molecular mechanisms of cancer-associated fibroblasts mediating therapeutic resistance in gastric cancer and targeted strategies
Chinese Journal of Clinical and Experimental Pathology 2025;41(10):1357-1364
Cancer-associated fibroblasts(CAFs),as major components of the tumor microenvironment,play a pivotal role in therapeutic resistance in gastric cancer.Evidence shows that CAFs contribute to resistance through vari-ous multiple mechanisms,including exosomal signaling,metabolic reprogramming,extracellular matrix remodeling,and immune modulation.Although the regulatory network of CAFs is highly complex and the clinical translation of relat-ed therapeutic strategies remains challenging,precise targeting CAFs offers a promising avenue for overcoming drug re-sistance and improving patient outcomes.This review summarizes the molecular mechanisms by which CAFs mediate resistance and signaling pathways,biomarker-based immunotherapy,and emerging combination regimens,aiming to provide novel insights for gastric cancer treatment.
5.Current situation of parturiophobia and its correlation with prenatal preferred delivery mode in Changning District, Shanghai
Yunmei SHI ; Qing CHEN ; An CHEN ; Anxin YIN ; Hong JIANG ; Fang BU ; Danjin WANG ; Shiyang CHENG
Chinese Journal of Perinatal Medicine 2023;26(3):201-208
Objective:To analyze the prevalence of parturiophobia and its association with preferred mode of delivery in pregnant women in Changning District, Shanghai.Methods:A cross- sectional study was conducted among 1 560 pregnant women in the third trimester who had their antenatal examination in Changning Maternity and Infant Health Hospital from September 2020 to March 2021. Fear of childbirth was measured with a validated Chinese version of Wijma Delivery Expectancy/Experience Questionnaire version A (W-DEQ-A). Based on the W-DEQ-A scores, the participants were divided into two groups: non-clinical parturiophobia group [<85 scores, including mild (≤37 scores), moderate (38-65 scores) and severe (66-84 scores) parturiophobia] and clinical parturiophobia group (≥85 scores). Rank-sum test, Chi-square test and t-test were used for univariate analysis. Multivariate binary logistic regression was used to analyze the factors associated with fear of childbirth and its relationship with preferred mode of delivery. Results:The detection rates of mild, moderate, severe and clinical parturiophobia were 18.8% (294/1 560), 44.9% (700/1 560), 31.1% (485/1 560) and 5.2% (81/1 560), respectively. Multivariate binary logistic regression showed that the participants who were supported by relatives and friends to have cesarean section ( OR=3.45, 95% CI: 1.29-9.22) or had antenatal anxiety ( OR=4.73, 95% CI: 2.49-8.97) were more likely to have clinical parturiophobia, while those with planned pregnancy ( OR=0.49, 95% CI: 0.29-0.82), high intensity physical activity ( OR=0.36, 95% CI: 0.18-0.72) or better/well understanding of the delivery process ( OR=0.42, 95% CI: 0.19-0.97) were less likely to develop clinical parturiophobia (all P<0.05). Compared with the non-clinical parturiophobia women, those with clinical parturiophobia were more likely to choose cesarean section ( OR=2.15, 95% CI: 1.22-3.78, P=0.008). Conclusions:The detection rates of severe and clinical parturiophobia are 31.1% and 5.2% in Changning District, Shanghai. The associated factors mainly include the attitudes of relatives and friends towards the mode of delivery, antenatal anxiety, planned pregnancy or not, physical activity level and the understanding of delivery process. Clinical parturiophobia might be an important factor for cesarean section on maternal request.
6.Research progress on gastrointestinal complications after lung transplantation
Haoji YAN ; Weiyang CHEN ; Zhenting WEI ; Meihan LIU ; Shiyang DENG ; Heng HUANG ; Kaiyuan JIANG ; Dong TIAN
Organ Transplantation 2020;11(6):749-
Due to the influence of immunosuppression, nerve injury and other comprehensive factors, the overall incidence of gastrointestinal complications after lung transplantation is relatively high, which can cause drug absorption disorder and chronic rejection. In recent years, more and more studies have been conducted on these complications. However, due to the great difference of the incidence of gastrointestinal complications among lung transplantation centers, clinicians lack of understanding of these. In this article, the general status, common types and risk factors of gastrointestinal complications after lung transplantation were reviewed, aiming to provide reference for comprehensive management of gastrointestinal complications after lung transplantation.
7.Analysis on correlation between severity of ulcerative colitis patients under endoscopy and laboratory examination indexes
Xiao LI ; Xin LIU ; Haitao SHI ; Yuan FENG ; Gang ZHAO ; Fenrong CHEN ; Jiong JIANG ; Danyan CHANG ; Juhui ZHAO ; Shiyang MA
Chinese Journal of Inflammatory Bowel Diseases 2020;04(2):119-123
Objective:To examine the correlation of the severity of ulcerative colitis (UC) under endoscopy with blood routine, coagulation, lipid, uric acid and other laboratory indexes.Methods:Clinical data of 90 UC patients in The Second Affiliated Hospital of Xi′an Jiaotong University from January to December 2018 were retrospectively collected. The patients were divided into three groups as light, medium and heavy according to Mayo colonoscopy score. The laboratory indexes were compared among 3 groups and the correlations between Mayo colonoscopy score and laboratory indexes were analyzed.Results:Among light, medium, and heavy groups, differences of the platelet count [ (205.00 ± 61.18) × 10 9/L vs. (240.33 ± 82.90) × 10 9/L vs. (285.55 ± 107.60) × 10 9/L, P=0.020], hemoglobin [ (129.70 ± 16.22) g/L vs. (135.35 ± 20.40) g/L vs. (121.33 ± 27.82) g/L, P=0.034], low-density lipoprotein (LDL) [ (2.44 ± 0.50) mmol/L vs. (2.54 ± 0.67) mmol/L vs. (2.10 ± 0.62) mmol/L, P=0.010], cholesterol [ (4.07 ± 0.60) mmol/L vs. (4.02 ± 0.94) mmol/L vs. (3.50 ± 0.80) mmol/L, P=0.017], fibrinogen [ (2656.00 ± 371.54) mg/L vs. (3034.50 ± 826.52) mg/L vs. (3390.26 ± 1013.61) mg/L, P=0.039] were statistically significant (all P<0.05) . Mayo colonoscopy score was negatively correlated with LDL and cholesterol (all P<0.05) , while it was positively correlated with platelet count and fibrinogen (all P<0.05) . Conclusion:Testing the relevant laboratory indexes of UC patients can help evaluate the intestinal condition.
8.Analysis on correlation between severity of ulcerative colitis patients under endoscopy and laboratory examination indexes
Xiao LI ; Xin LIU ; Haitao SHI ; Yuan FENG ; Gang ZHAO ; Fenrong CHEN ; Jiong JIANG ; Danyan CHANG ; Juhui ZHAO ; Shiyang MA
Chinese Journal of Inflammatory Bowel Diseases 2020;04(2):119-123
Objective:To examine the correlation of the severity of ulcerative colitis (UC) under endoscopy with blood routine, coagulation, lipid, uric acid and other laboratory indexes.Methods:Clinical data of 90 UC patients in The Second Affiliated Hospital of Xi′an Jiaotong University from January to December 2018 were retrospectively collected. The patients were divided into three groups as light, medium and heavy according to Mayo colonoscopy score. The laboratory indexes were compared among 3 groups and the correlations between Mayo colonoscopy score and laboratory indexes were analyzed.Results:Among light, medium, and heavy groups, differences of the platelet count [ (205.00 ± 61.18) × 10 9/L vs. (240.33 ± 82.90) × 10 9/L vs. (285.55 ± 107.60) × 10 9/L, P=0.020], hemoglobin [ (129.70 ± 16.22) g/L vs. (135.35 ± 20.40) g/L vs. (121.33 ± 27.82) g/L, P=0.034], low-density lipoprotein (LDL) [ (2.44 ± 0.50) mmol/L vs. (2.54 ± 0.67) mmol/L vs. (2.10 ± 0.62) mmol/L, P=0.010], cholesterol [ (4.07 ± 0.60) mmol/L vs. (4.02 ± 0.94) mmol/L vs. (3.50 ± 0.80) mmol/L, P=0.017], fibrinogen [ (2656.00 ± 371.54) mg/L vs. (3034.50 ± 826.52) mg/L vs. (3390.26 ± 1013.61) mg/L, P=0.039] were statistically significant (all P<0.05) . Mayo colonoscopy score was negatively correlated with LDL and cholesterol (all P<0.05) , while it was positively correlated with platelet count and fibrinogen (all P<0.05) . Conclusion:Testing the relevant laboratory indexes of UC patients can help evaluate the intestinal condition.
9. Major findings from the 4th Evaluation of the National Healthcare Improvement Initiative
Jing SUN ; Feng JIANG ; Linlin HU ; Yu JIANG ; Jing MA ; Li LUO ; Ying MAO ; Guo ZHANG ; Jinliang HU ; Bingjie SHEN ; Yinuo WU ; Peiwen ZHANG ; Jialin JI ; Ran GUO ; Meicen LIU ; Shichao WU ; Shiyang LIU ; Zijuan WANG ; Yuanli LIU
Chinese Journal of Hospital Administration 2019;35(9):705-711
Objective:
To carry out the 4th round of third-party evaluation on the implementation and effect of the 1st year of the 2nd Phase National Healthcare Improvement Initiative(abbreviated as Initiative)since 2015.
Methods:
The 4th round of the evaluation survey adopted the same methods, organization and execution, and technical roadmap as the former three rounds of evaluations.
Results:
The 4th round of evaluation was carried out from 18 March to 9 April, 2019 at 185 public hospitals in 31 provinces(autonomous regions, municipalities directly under the Central Government)and Xinjiang Production and Construction Corps.Facility survey, health professional survey and patient survey were conducted at each of the sample health facilities. A total of 120 782 valid questionnaires were collected from 144 non-psychiatric health facilities, 16 246 valid questionnaires were obtained from 41 psychiatric health facilities, and 252 cases of outstanding departments/hospitals in healthcare improvement were also collected. The average overall scoring of the 12 dimensions to assess Initiative implementation at 144 non-psychiatric health facilities was 84.4%. The overall outpatient satisfaction scoring was 91.1%, 96.7%for the inpatients. The overall inpatient satisfaction(family members inclusive) at 41 psychiatric health facilities was 93%. Areas remaining to be improved include day-surgery, telemedicine and medical social work. Compared with technical services, non-technical care should be further strengthened. The compensation, workload and work environment of the healthcare providers are still to be improved.
Conclusions
The implementation of the Initiative by health facilities has been greatly improved. The percentage of health facilities and patients who had positive perceptions of improved doctor-patient relationship has been increasing. Patient care experiences at public hospitals have been generally improved, and the implementation of promoting traditional Chinese Medicine practices also made progress. However, work satisfaction of healthcare providers was found to be rather low, compared to the high level of patient satisfaction.
10.Effects of prophylactic chemotherapy on outcomes and prognosis of patients older than 40 years with invasive mole
Shiyang JIANG ; Ling LI ; Jun ZHAO ; Yang XIANG ; Xirun WAN ; Fengzhi FENG ; Tong REN ; Junjun YANG
Chinese Journal of Obstetrics and Gynecology 2017;52(6):398-402
Objective To discuss the effects of prophylactic chemotherapy on the outcomes and prognosis of invasive mole patients.Methods One hundred and fifteen invasive mole (IM) patients older than 40 years were registered in Peking Union Medical Collage Hospital.Eleven of them were treated with prophylactic chemotherapy before diagnosed as IM prophylactic chemotherapy group,while the other 104 cases received therapeutic chemotherapy after diagnosed as IM (non-prophylactic chemotherapy group).The general clinical data (including age,clinical stage,risk factor score),treatment,outcomes and relapse of patients were retrospectively compared between two groups.Results (1) The age of prophylactic chemotherapy group and non-prophylactic chemotherapy group were (47±5) versus (46±4) years old.Ratio of clinical stage Ⅰ-Ⅱ were 3/11 versus 29.8% (31/104),clinical stage Ⅲ-Ⅳ were 8/11 versus 70.2% (73/104).Ratio of risk factor score 0-6 were 11/11 versus 84.6% (88/104),risk factor score >6 were 0 versus 15.4%(16/104).There were no significant statistical differences between two groups in age,clinical stage or risk factor score (all P>0.05).(2) Treatment:the total chemotherapy courses between prophylactic chemotherapy group and non-prophylactic chemotherapy group (median 7 versus 5) were significantly different (Z=3.071,P=0.002).There were no significant statistical differences between two groups in the chemotherapy courses until negative conversion of β-hCG,consolidation chemotherapy courses,total therapeutic chemotherapy courses or ratio of hysterectomy (all P>0.05).(3) Outcomes and relapse:between the prophylactic chemotherapy group and the non-prophylactic chemotherapy group,the complete remission rate were 11/11 versus 98.1%(102/104),the relapse rate were 0 versus 1.0%(1/102).There were no significant difference between the two groups in outcomes or relapse rate (P>0.05).Conclusions Prophylactic chemotherapy does not substantially benefit the IM patients older than 40 years.Prophylactic chemotherapy may not significantly improve patients' prognosis,in which increased sample size is required in further study.

Result Analysis
Print
Save
E-mail